Erasca Inc
0.28 (9.46%)


Draw Mode:

Volume 200
Bid Price 3.03
Ask Price 3.25
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Erasca Inc ERAS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.28 9.46% 3.24 05:09:17
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
2 200 - 2.65 - 10.74
Last Trade Time Type Quantity Stock Price Currency
05:09:17 formt 100 $ 3.24 USD

Erasca Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 487.91M 150.59M 105.60M $ - $ - -1.99 -4.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.93M 0.90%

more financials information »

Erasca News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ERAS Message Board. Create One! See More Posts on ERAS Message Board See More Message Board Posts

Historical ERAS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.943.21992.652.831,117,9290.3010.2%
1 Month3.473.582.653.121,309,107-0.23-6.63%
3 Months4.414.572.653.591,087,564-1.17-26.53%
6 Months7.849.252.654.781,027,131-4.60-58.67%
1 Year9.5010.742.655.67765,911-6.26-65.89%
3 Years15.9024.472.658.78681,146-12.66-79.62%
5 Years15.9024.472.658.78681,146-12.66-79.62%

Erasca Description

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.